International Stem Cell Corporation Secures $1,000,000 New Funding Round

  • Feed Type
  • Date
    1/23/2009
  • Company Name
    International Stem Cell Corporation
  • Mailing Address
    2595 Jason Court Oceanside, CA 92056
  • Company Description
    The Company was founded for the specific purposes of solving key problems in the emerging field of regenerative medicine, cell availability and immune rejection. There are growing numbers of cell transplant therapies that have already been demonstrated to be effective in treating major diseases such as diabetes, liver disease and retinal disease, and many others. What is not available is a reliable, renewable and essentially unlimited source of human cells for use in these transplant procedures. Existing embryonic stem cell lines produce cells that will be difficult to match to the patient’s immune system. Parthenogenetic stem cells can solve both of these problems.
  • Website
    http://www.internationalstemcell.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The total amount of the financing is intended to allow the Company to move forward with its therapeutic research, including its pre-clinical trials. The money will also help retire its existing secured debt and be allocated to marketing to increase revenues in the Company’s subsidiary, Lifeline Cell Technology, which makes and sells specialty cells and growth media.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy